Vees et al. (41), 2007 | BJU Int | 11 | 66 | ND | Mean, 0.06 (0.00–0.51) | |
Buchegger et al. (43), 2014 | EJNMMI | 23 | ND | ND | Mean, 1.1 after prostatectomy, 3.5 after radiotherapy, 2.4 after prostatectomy + salvage radiotherapy | High concordance between 18F-choline and 11C-acetate findings |
Kotzerke et al. (44), 2002 | EJNMMI | 31 | ND | ND | Mean, 15.2 (0.1–150.6) | 15 of 18 patients (83%) with biopsy-proven recurrence were true-positive; 5 of 8 (63%) were 11C-acetate–positive with PSA < 2.0 ng/mL (4 of these 5 had histologically proven disease) |
Oyama et al. (45), 2003 | J Nucl Med | 46 | 59 | ND | Mean, 4.9 (0.3–47.5) after prostatectomy, 5.8 (0.5–11.5) after radiotherapy, PSA threshold of 3 ng/mL | 13 of 22 patients (59%) with PSA > 3 ng/mL were 11C-acetate–positive; 1 of 24 (4%) with PSA ≤ 3 ng/mL was 11C-acetate–positive |
Albrecht et al. (47), 2007 | EJNMMI | 32 | ND | ND | Mean, 10.4 (2.6–30.2) after radiotherapy, 1.2 (0.08–4.8) after radical surgery | 14 of 17 patients (82%) after radiotherapy were 11C-acetate–positive; 5 of 15 (33%) after radical surgery were 11C-acetate–positive |
Sandblom et al. (48), 2006 | Urology | 20 | 75 | ND | Median, 2.0 (0.5–8.1) | |
Dusing et al. (49), 2014 | Clin Nucl Med | 120 | 74*, 87† | 75*, 66† | Mean, 7.6 (in 119 patients, 0.20–127.32) | |
Wachter et al. (52), 2006 | J Clin Oncol | 50 | 92 | 60 | Range, 0.5–24.9 | In 12 patients with histopathologic verification |
Spick et al. (54), 2015 | Anticancer Res | 90 | 90 | 96.1 | Mean, 41.8 (0.3–551.1) | In bone metastasis |
Total | | 423 | | | | |